Hendrik Dietz

Overview

Founder/CEO of CBTX, former academic researcher pioneering in vivo CAR-T therapy using immune-quiet single-stranded DNA delivered by targeted LNPs. Hendrik Dietz transitioned from an academic career as a renowned scientist to founding CBTX, a biotech advancing a next-generation in vivo T-cell programming platform for making in vivo CAR-T products. CBTX's single-stranded DNA payload is 7,000 bases long and not commercially available at scale; Dietz's lab developed a microbial fermentation process more than 12 years ago to produce it in quantities above one milligram. (Segment 1 (00:00-05:00))